Inquire Now
Key strategic points
RNA therapeutics are a class of medicines that use ribonucleic acid (RNA) molecules to modulate gene expression, replace faulty proteins, or regulate cellular functions to treat diseases. It includes mRNA therapies, siRNA therapies, antisense oligonucleotides (ASOs), microRNA therapeutics, and other RNA-based platforms.
The market encompasses the research, development, manufacturing, and commercialization of RNA-based therapies designed to prevent, treat, or manage diseases by targeting specific RNA molecules in the body.
The global RNA therapeutics market size was valued at USD 7.66 billion in 2024 and is projected to grow from USD 8.50 billion in 2025 to USD 19.60 billion by 2032, exhibiting a CAGR of 12.67% over the forecast period.
Market growth is driven by the increasing prevalence of genetic and rare diseases, which is fueling demand for precision-targeted RNA-based therapies. The advancement of RNA delivery technologies, such as lipid nanoparticles, polymeric carriers, and conjugate-based systems, is further supporting the development of safer and more effective therapies.
Major companies operating in the RNA therapeutics market are Moderna, Inc, BioNTech SE, Alnylam Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc, Pfizer Inc, Sarepta Therapeutics, Inc, Arcturus Therapeutics, Inc, CureVac SE, Arrowhead Pharmaceuticals, Inc, Silence Therapeutics, Novartis AG, AstraZeneca, ReCode Therapeutics, Inc, Orna Therapeutics, Inc, and Creyon Bio, Inc.
Increasing collaboration between biotech and pharmaceutical companies is driving the development of novel RNAi-based therapies, thereby driving market growth. Additionally, the expansion of specialized RNAi platforms, combined with clinical development and regulatory expertise, is accelerating the adoption of innovative RNA-based therapeutics.
Rising Prevalence of Genetic and Chronic Diseases
A key factor propelling the growth of the RNA therapeutics market is the rising prevalence of genetic and chronic diseases. Increasing incidences of inherited disorders, rare diseases, and chronic conditions such as cancer, cardiovascular, and metabolic disorders are creating a need for innovative therapies.
Pharmaceutical companies are focusing on the development of RNA-based therapies, including mRNA, siRNA, and antisense oligonucleotides, to provide targeted and precision-based treatment.
Healthcare providers are increasingly adopting these innovative therapies to address unmet medical needs and improve patient outcomes. This growing emphasis on personalized and effective treatment options is accelerating demand for RNA-based therapeutics and driving market growth.
High Development and Manufacturing Costs
A key challenge limiting the growth of the RNA therapeutics market is the high development and manufacturing costs of advanced RNA-based therapies. Producing mRNA, siRNA, and antisense oligonucleotides requires specialized equipment, complex synthesis, purification, and delivery systems, along with extensive preclinical and clinical testing. Strict quality control and regulatory compliance further increase production expenses and limit market growth.
To address this challenge, market players are investing in advanced production technologies and automated manufacturing processes to improve efficiency and reduce expenses in RNA-based therapeutics.
Companies are forming strategic partnerships with contract development and manufacturing organizations (CDMOs) to share expertise and infrastructure for efficient production of RNA therapeutics. Additionally, they are adopting scalable manufacturing platforms to enable faster scale-up and support the efficient commercialization of RNA-based therapeutics.
Integration of AI in RNA Therapeutics and Delivery Platforms
A key trend influencing the RNA therapeutics market is the integration of artificial intelligence (AI) in RNA therapeutic design and delivery platforms. Companies are leveraging AI to optimize RNA sequences, predict molecular interactions, and enhance delivery efficiency to target cells and tissues.
This is improving therapeutic precision, reducing off-target effects, and increasing overall efficacy. The growing focus of key players on AI-driven innovation is accelerating the development of safer and personalized RNA-based therapies across genetic disorders and central nervous system conditions.
|
Segmentation |
Details |
|
By Type |
mRNA-based Therapeutics, RNA Interference, Antisense Oligonucleotides, Others |
|
By Indication |
Infectious Diseases, Oncology, Cardiovascular Disorders, Neurological Disorders, Others |
|
By End User |
Hospitals & Clinics, Research & Academic Institutes, Biopharmaceutical & Biotechnology Companies, Contract Research and Manufacturing Organizations |
|
By Region |
North America: U.S., Canada, Mexico |
|
Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe |
|
|
Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific |
|
|
Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa |
|
|
South America: Brazil, Argentina, Rest of South America |
Based on region, the market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
North America RNA therapeutics market share stood at 37.65% in 2024 in the global market, valued at USD 2.88 billion. This dominance is driven by the increasing prevalence of genetic and rare diseases across the region. Rapid advancements in RNA delivery technologies, such as lipid nanoparticles and polymeric carriers are improving the stability and efficacy of therapeutics to ensure efficient targeting in specific cells or tissues.
Growing adoption of mRNA vaccines and RNA-based therapies is expanding their use across healthcare to address a wider range of diseases and improve patient outcomes. Additionally, regional players are forming strategic collaborations to accelerate research, development, and commercialization of RNA therapeutics, thereby driving market growth across the region.
Asia Pacific is set to grow at a CAGR of 14.01% over the forecast period. This growth is driven by the rapid expansion of healthcare infrastructure and the increased availability of advanced therapies across the region. The rising prevalence of infectious diseases and genetic disorders is creating strong demand for RNA-based vaccines and therapies.
The expansion of clinical research networks and contract manufacturing organizations in the region is enabling faster development of RNA therapeutics. Additionally, regional players are focusing on strategic collaborations to strengthen research capabilities, facilitate technology transfers, and establish local RNA manufacturing infrastructure, thereby boosting market growth.
Major players in the RNA therapeutics industry are actively developing next-generation delivery platforms to improve stability, targeting, and efficacy of RNA-based therapies. They are adopting artificial intelligence and bioinformatics tools to design optimized RNA sequences and streamline the discovery of novel therapeutics. Additionally, players are focusing on strategic collaborations to improve production infrastructure and expand their therapeutic portfolio and market presence.
Frequently Asked Questions
Swati is a committed research analyst with a passion for optimizing systems and processes across industries, specializing in healthcare but also bringing valuable expertise to sectors such as consumer goods, life sciences, and more. Her cross-domain research approach allows her to generate clear, actionable reports that inform strategic decisions in a variety of fields. Swati is committed to staying ahead of evolving trends, leveraging her broad understanding of different sectors to provide insights that are relevant to a range of industries. In her personal time, she enjoys music and spending quality time with her family, which inspires her creativity and enriches her professional approach. Her systematic methodology ensures that every report is both thorough and practical. Swati's ability to bridge regulatory frameworks with market realities gives her recommendations a distinct edge. She collaborates seamlessly with cross-functional teams, distilling complex data into straightforward narratives. Her proactive monitoring of policy and technological shifts keeps her analysis forward-looking.
With over a decade of research leadership across global markets, Ganapathy brings sharp judgment, strategic clarity, and deep industry expertise. Known for precision and an unwavering commitment to quality, he guides teams and clients with insights that consistently drive impactful business outcomes.
